Can a cancer pill keep bone sarcomas at bay?

NCT ID NCT04055220

Recruiting now Disease control Sponsor: Centre Leon Berard Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether the drug regorafenib can help prevent bone sarcomas from coming back after initial treatment. About 168 people aged 12 and older with various bone sarcomas will be randomly assigned to take regorafenib for up to 12 months or to receive standard monitoring. The goal is to see if regorafenib improves relapse-free survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Regorafenib (Stivarga)
What this could lead to: If it works, this could provide a new maintenance option to delay relapse in bone sarcoma patients after initial treatment.
What could go wrong: This is an early phase II exploratory study, so results are uncertain. Regorafenib has side effects like fatigue, hand-foot skin reaction, and liver issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

angiosarcoma bone cancer bone sarcoma chondrosarcoma Ewing sarcoma leiomyosarcoma osteosarcoma Pathologic Complete Response Patient Compliance undifferentiated pleomorphic sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANGIOSARCOMA BONE SARCOMA CHONDROSARCOMA EWING SARCOMA LEIOMYOSARCOMA OSTEOSARCOMA UNDIFFERENTIATED PLEOMORPHIC SARCOMA

Contacts and locations

Locations

APHM - Hôpital Timone
RECRUITING

Marseille, 13385, France
APHP Hôpital Cochin
RECRUITING

Paris, 75014, France
Centre Hospitalier Régional de Strasbourg Hautepierre
RECRUITING

Strasbourg, 67098, France
Centre Hospitalier Universitaire de Poitiers
NOT_YET_RECRUITING

Poitiers, 86000, France
Centre Hospitalier Universitaire de Saint-Etienne (CHUSE)
RECRUITING

Saint-Etienne, 42055, France
Centre Léon Bérard
RECRUITING

Lyon, 69373, France
Centre Oscar Lambret
RECRUITING

Lille, 59020, France
Centre Paul Strauss - Strasbourg
RECRUITING

Strasbourg, 67033, France
Hôpital Jean Minjoz
RECRUITING

Besançon, 25000, France
ICL Alexis Vautrin
NOT_YET_RECRUITING

Vandœuvre-lès-Nancy, 54519, France
ICM Val d'Aurelle
NOT_YET_RECRUITING

Montpellier, 34298, France
ICO René Gauducheau
RECRUITING

Saint-Herblain, 44805, France
IUCT-Oncopole
NOT_YET_RECRUITING

Toulouse, 31059, France
Institut Bergonié
RECRUITING

Bordeaux, 33076, France
Institut Curie
RECRUITING

Paris, 75005, France
Institut Gustave Roussy
RECRUITING

Villejuif, 94805, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.